https://www.selleckchem.com/pr....oducts/bms-927711.ht
8-4.1%). Most cases were not serious (old formulation, 65.8%; new formulation, 78.7%). Reporting rates were similar or higher for the old formulation within subgroups of at-risk patients. Nature/distributions of adverse events by thyroid-stimulating hormone levels as determined by both the marketing authorization holder of levothyroxine and the French National Agency for Medicines and Health Products Safety were similar. The new formulation safety profile aligns with the established profile of the old formulation of levothyroxine. Th
Like
Comment
Share
